Ysios Capital Investors
Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society. ... The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen ...
Technology:
N/A
Headquarters:
Spain
Funding Status:
N/A
Investment Stage:
Early Stage Venture, Late Stage Venture, Venture
Founded Date:
2008-01-01
Number Of Exists:
13
Employee Number:
11-50
Industry:
Asset Management
Investor Type:
Technology - oriented Investor with Venture Investment Focus